{ "items": [ "\n\n
\n \n 1 August 2023\n \n
\n\n \n \n \n\n \n \n \nLast week, the University of Oxford\u2019s historic Divinity School hosted a special evening event to celebrate the seven new community-led research collaborations formed over the last 12 months through the Science Together engagement programme.
\n \n\n\n \n 31 July 2023\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford-developed, Serum Institute of India PvT Ltd (SIIPL) manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax\u2019s adjuvant technology, has been licensed for use in Burkina Faso by the country\u2019s regulatory agency, Agence Nationale de la Regulation Pharmaceutique (ANRP).
\n \n\n\n \n 31 July 2023\n \n
\n\n \n \n \n\n \n \n \nFor the first time, Oxford chemists have generated fluorochemicals \u2013 critical for many industries \u2013 without the use of hazardous hydrogen fluoride gas. The team\u2019s innovative method, published this week in the leading journal Science, could achieve an immense impact in improving the safety and carbon footprint of a growing global industry.
\n \n\n\n \n 31 July 2023\n \n
\n\n \n \n \n\n \n \n \nOxford researchers have been given a \u00a31 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.
\n \n\n\n \n 31 July 2023\n \n
\n\n \n \n \n\n \n \n \nRoutine brain scanning in people experiencing psychosis could help to identify underlying physical conditions that are causing their symptoms, according to a new study.
\n \n\n\n \n 31 July 2023\n \n
\n\n \n \n \n\n \n \n \nWhy do some people take part in genetic studies while others do not? The answer may lie within our genetic makeup. According to a ground-breaking study by Oxford's Leverhulme Centre for Demographic Science and Big Data Institute, people who participate in genetic studies are genetically more likely to do so, leaving detectable \u2018footprints\u2019 in genetics data. This breakthrough equips researchers with the ability to identify and address participation bias, a significant challenge in genetic research.
\n \n\n\n \n 31 July 2023\n \n
\n\n \n \n \n\n \n \n \nA research study led by the University of Oxford provides a transformational new insight into how antimicrobial resistance (AMR) emerges in patients with bacterial infections. The findings, published today in the journal Nature Communications, could help develop more effective interventions to prevent AMR infections developing in vulnerable patients.
\n \n\n\n \n 31 July 2023\n \n
\n\n \n \n \n\n \n \n \nThe multisite Phase I HIV-CORE 006 HIV vaccine clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully.
\n \n\n\n \n 28 July 2023\n \n
\n\n \n \n \n\n \n \n \nRepresentatives from academia, industry, policy and civil society are gathering in Oxford next week to discuss the latest scientific advances that are ensuring the world is better prepared for future pandemics.
\n \n\n\n \n 28 July 2023\n \n
\n\n \n \n \n\n \n \n \nResearchers running the University of Oxford-led Com-COV3 study have reported the results of a study assessing the immune response and side effect profile of \u2018mixed\u2019 two-dose COVID-19 vaccine schedules in adolescents aged 12 to 16 years - administering either a full or a one-third (fractional) dose of the Pfizer-BioNTech COVID-19 vaccine or a full dose of the Novavax vaccine at least eight weeks after a first full dose of the Pfizer-BioNTech vaccine.
\n \n\n